Total submissions: 5
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000540736 | SCV000625607 | uncertain significance | Hereditary nonpolyposis colorectal neoplasms | 2024-11-19 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 761 of the PMS2 protein (p.Val761Ile). The frequency data for this variant in the population databases (gnomAD) is considered unreliable due to the presence of homologous sequence, such as pseudogenes or paralogs, in the genome. This variant has not been reported in the literature in individuals affected with PMS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 455698). Invitae Evidence Modeling incorporating data from in vitro experimental studies (internal data) indicates that this missense variant is not expected to disrupt PMS2 function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV000569407 | SCV000674229 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-12-05 | criteria provided, single submitter | clinical testing | The p.V761I variant (also known as c.2281G>A), located in coding exon 14 of the PMS2 gene, results from a G to A substitution at nucleotide position 2281. The valine at codon 761 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |
| Gene |
RCV001557186 | SCV001778905 | uncertain significance | not provided | 2019-10-16 | criteria provided, single submitter | clinical testing | Not observed at a significant frequency in large population cohorts (Lek 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV003317257 | SCV004020713 | uncertain significance | not specified | 2023-06-15 | criteria provided, single submitter | clinical testing | |
| Baylor Genetics | RCV004568723 | SCV005056385 | uncertain significance | Lynch syndrome 4 | 2024-03-22 | criteria provided, single submitter | clinical testing |